{
  "extraction_date": "2025-12-23",
  "condition": "FIBROMYALGIA",
  "phase": "3",
  "priority": "Expansion",
  "total_studies": 2,
  "studies": [
    {
      "study_id": "CT_NCT06138171",
      "study_type": "Clinical Trial",
      "condition": "FIBROMYALGIA",
      "study_title": "Personality, Defences, Central Sensitization, and Trauma in Women With Chronic Migraine, Fibromyalgia, and Vulvodynia",
      "citation": "ClinicalTrials.gov NCTNCT06138171",
      "publication_year": 2024,
      "journal": "ClinicalTrials.gov",
      "intervention": {
        "cannabis_type": "cannabis/cannabinoids",
        "cannabinoid_profile": "Cannabis mentioned in study text",
        "delivery_method": "various",
        "dosing_information": "Phase N/A",
        "treatment_duration": "clinical trial duration"
      },
      "outcomes": {
        "key_findings": [
          "Central sensitivity index",
          "Traumatic experiences index",
          "Personality traits",
          "Defense mechanisms",
          "Mental pain",
          "Environmental sensitivity"
        ],
        "outcome_measures": [
          "Central sensitivity index",
          "Traumatic experiences index",
          "Personality traits",
          "Defense mechanisms",
          "Mental pain",
          "Environmental sensitivity"
        ],
        "adverse_events": [],
        "evidence_rating": "medium",
        "confidence_level": "medium"
      },
      "metadata": {
        "nct_id": "NCT06138171",
        "enrollment": 1006,
        "phase": "N/A",
        "source": "ClinicalTrials.gov",
        "url": "https://clinicaltrials.gov/study/NCT06138171"
      }
    },
    {
      "study_id": "CT_NCT05939466",
      "study_type": "RCT",
      "condition": "FIBROMYALGIA",
      "study_title": "Medical Cannabis for Treating Pain Related to Fibromyalgia",
      "citation": "ClinicalTrials.gov NCTNCT05939466",
      "publication_year": 2021,
      "journal": "ClinicalTrials.gov",
      "intervention": {
        "cannabis_type": "cannabis/cannabinoids",
        "cannabinoid_profile": "Bedrocan\u00ae-type cannabis (22% THC, <1% CBD)",
        "delivery_method": "various",
        "dosing_information": "Phase PHASE4",
        "treatment_duration": "clinical trial duration"
      },
      "outcomes": {
        "key_findings": [
          "Pain intensity",
          "Physical state",
          "Mental state"
        ],
        "outcome_measures": [
          "Pain intensity",
          "Physical state",
          "Mental state"
        ],
        "adverse_events": [],
        "evidence_rating": "medium",
        "confidence_level": "medium"
      },
      "metadata": {
        "nct_id": "NCT05939466",
        "enrollment": 30,
        "phase": "PHASE4",
        "source": "ClinicalTrials.gov",
        "url": "https://clinicaltrials.gov/study/NCT05939466"
      }
    }
  ],
  "expansion_metadata": {
    "clinicaltrials_gov_added": 2,
    "pubmed_added": 0,
    "total_added": 2,
    "expansion_date": "2025-12-23T23:42:11.460085"
  }
}